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1 |  BACKGROUND
In September 2018, in the wake of extensive media cover-
age and sanctions placed on a significant number of residen-
tial aged care facilities (RACFs), the Hon. Ken Wyatt, the 
Minister for Senior Australians and Aged Care, announced a 
Royal Commission into Aged Care Quality and Safety. The 
Royal Commission commenced on 11 February 2019 and has 
had, to date, a strong focus on both overuse and inappropriate 
use of physical and chemical restraint and the lack of consent 
for the use of restraint in aged care. Minister Wyatt was out-
spoken about his desire to tackle these issues and on 2 April 
2019 made the Quality of Care Amendment (Minimising the 
Use of Restraints) Principles 2019. Section 96-1 of the Aged 
Care Act 1997 (Aged Care Act) provides that the Minister 
may, by legislative instrument, make Quality of Care 
Principles, providing for matters required or permitted by Part 
4.1 of the Act. The Quality of Care Amendment (Minimising 
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Abstract
Objective: To explore the meaning and potential role of new Quality of Care 
Amendment (Minimising the Use of Restraints) Principles 2019, (Principles) which 
amend Quality of Care Principles 2014 in improving practice around physical and 
chemical restraint.
Methods: We examined both Principles and accompanying Explanatory Statement 
in light of best practices around consent and use of chemical and physical restraint.
Results: The chemical restraint definition is problematic by exclusion of medica-
tions for treating mental disorders, physical illness or physical conditions, which is 
not considered restraint. Inexplicably, physical restraint requirements are more rigor-
ous than chemical restraint requirements, where assessment is optional, and consent 
sometimes obtained, after use, and from the person's “representative,” rather than the 
person first, followed by their proxy decision-maker.
Conclusion: Although a start in promoting best practice around physical restraint, 
the Principles do not address the status quo of poor practice around chemical restraint 
and may instead codify it.
K E Y W O R D S
dementia, law, residential care, restraints
2 |   PEISAH Et Al.
the Use of Restraints) Principles 2019 (Amending Principles) 
amends the Quality of Care Principles 2014 (Quality of Care 
Principles) to limit the use of chemical and physical restraint 
by approved providers of residential care and short-term re-
storative care in a residential setting (https ://www.legis la-
tion.gov.au/Detai ls/F2019 L00511). The previous Quality of 
Care Principles 2014 referred to neither chemical restraint 
nor consent.
The overuse and misuse of both chemical and physi-
cal restraint may constitute elder abuse1 and has long been 
identified as problematic,2,3 and in some ways getting worse 
where psychotropic prescribing is concerned.4,5 The use of 
restraints has been driven by a need to “manage” disturbed 
perception, thinking, mood and behaviour arising in the con-
text of dementia, also known as behavioural and psychologi-
cal symptoms of dementia (BPSD) or changed behaviours.6,7 
BPSD include aggression, agitation, wandering, anxiety and 
depression and are often an expression of unmet needs such 
as pain, loneliness or need for intimacy, hunger, boredom 
and overstimulation.3 As such, international consensus best 
practice guidelines recommend the use of multidisciplinary, 
individualised, psychosocial approaches as the first-line ap-
proach to BPSD. Such person-centred care relies on obser-
vation, measurement and monitoring of BPSD to assess the 
antecedents, triggers and consequences of behaviours.3,8-11 
Only after these person-centred non-pharmacological ap-
proaches have been trialled and failed, or there are risks to the 
safety of the person or those around them, should any type of 
restraint be used.3 For these reasons, and human rights con-
cerns,12 restraint use should be avoided where possible.
Despite these guidelines, more often than not there is re-
course to chemical or physical restraint,2-5 usually without 
consent from the person or their proxy decision-maker.13 
Under Common Law, no treatment can be undertaken with-
out consent of the person if they are a competent adult (ie a 
person with capacity to make the decision).14 For valid con-
sent, the person must be: (a) competent (have capacity) to 
make the treatment decision (in this case, restraint); (b) acting 
voluntarily without pressure or duress; and (c) provided with 
enough relevant information about the treatment options, al-
ternatives and material risks, presented in a form that can be 
understood to enable the person to make the decision.14 There 
is a presumption of capacity for all adults, regardless of their 
diagnosis or whether they live in a nursing home, and a valid 
“trigger” must exist to rebut this presumption and prompt an 
assessment. If a practitioner assesses a person as lacking ca-
pacity to give consent to treatment, they must seek consent 
from a proxy decision-maker, a process governed by various 
legislative regimes across Australia.14
Lack of consent has long been recognised as a problem 
internationally. In 1990, a study of Massachusetts nursing 
homes showed that informed consent was not considered 
an issue and decision-making capacity was not tested. The 
usual practice was for capacity to be presumed until a patient 
failed to acquiesce to treatment, and only at that point would 
the issue of capacity be fully addressed.15 Despite policies 
and guidelines mandating consent, and a range of interna-
tional initiatives to educate clinicians about consent,14,16 
proper consent is obtained in only about 6.5% of cases.17 In 
the Australian HALT study of 140 RACF residents taking 
antipsychotic medications for changed behaviours across 
23 RACFs, only one case met the NSW legal requirement 
of written proxy consent. Another 20 participants had a file 
note recording a conversation between a clinician and a fam-
ily member, leaving 84% of participants with no evidence of 
a consent process.13
The issues surrounding the use of restraint are many and 
complex. This paper aims to explore the meaning and poten-
tial role of the new Quality of Care Amendment (Minimising 
the Use of Restraints) Principles 2019, hereafter known as 
“The Principles” in improving practice around physical and 
chemical restraint, and its limitations in doing so.
2 |  METHOD
We examined both the Principles and their accompanying 
Explanatory Statement in light of international consensus 
best practice guidelines around both consent and the use of 
psychotropics. The Principles provide definitions of chemi-
cal and physical restraint under Schedule 1. Conditions 
for the use of chemical and physical restraint are also pro-
vided under Part 4A—Minimising the use of Physical and 
Chemical Restraint, including the steps Providers must take 
before using such restraints.
3 |  RESULTS
3.1 | Definitions
It is noted that under Schedule 1—Amendments, 1. Section 
4:
chemical restraint means a restraint that is, 
or that involves, the use of medication or a 
Practice Impact
Clinicians need to be mindful that improved prac-
tice around chemical restraint and consent beyond 
the new Quality of Care Amendment (Minimising 
the Use of Restraints) Principles 2019 legislation is 
urgently needed.
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chemical substance for the purpose of influenc-
ing a person’s behaviour, other than medication 
prescribed for the treatment of, or to enable 
treatment of, a diagnosed mental disorder, a 
physical illness or a physical condition.
physical restraint means any restraint other 
than:
(a) a chemical restraint; or
(b) the use of medication prescribed for the 
treatment of, or to enable treatment of, a diag-
nosed mental disorder, a physical illness or a 
physical condition.
restraint means any practice, device or action 
that interferes with a consumer’s ability to 
make a decision or restricts a consumer’s free 
movement.
Specifically, with regard to chemical restraint, the 
Explanatory Statement expands on this, stating: “it is not 
chemical restraint if those medications are used to treat a di-
agnosed mental disorder” (eg antipsychotics to treat psycho-
sis associated with disorders such as schizophrenia or bipolar 
disorder).
This definition of chemical restraint in the legislation is 
problematic by the exclusion of “mental disorder, a physical 
illness or a physical condition.” Read in isolation, without 
the caveat in the Explanatory Statement that antipsychotics 
used to treat psychosis in mental disorder is not chemical 
restraint, there is a risk that this will be interpreted as an 
“opt-out clause” for best practice minimisation of chemical 
restraint and the obtaining of consent in these circumstances. 
Specifically, antipsychotics used to influence behaviour 
per se in serious mental disorders still constitute restraint. 
Prescribing these medications also still requires consent. 
Older people with mental illness in residential care—whose 
needs are complex, yet often unmet18,19—equally deserve 
best practice approaches from aged care providers. This in-
cludes minimisation of chemical restraint, using person-cen-
tred assessment and careful consideration of the reasons for, 
and alternatives to restraint. A practical example is the older 
person with schizophrenia, who is sexually disinhibited or 
aggressive because of unmet intimacy needs or loneliness. 
Using antipsychotics or other psychotropics to treat this is 
still chemical restraint regardless of whether the person has 
schizophrenia.
Other potential misinterpretations of these exclusion cri-
teria for chemical restraint include delirium caused by a phys-
ical illness or physical condition, treatment recommendations 
for which no longer include psychotropics.20 Thus, although 
the legislation suggests otherwise, treating behavioural dis-
turbance in delirium still constitutes chemical restraint. 
Finally, many clinicians would argue that dementia itself is 
very much a “physical condition” as it involves neurodegen-
erative disease, thereby potentially excluding the treatment 
of behaviour disturbance in dementia from the definition of 
chemical restraint.
Exceptions to what is covered by the definition of chemi-
cal restraint are too wide, potentially rendering the legislation 
ineffective in reducing its misuse or overuse.
3.2 | Conditions for use of chemical and 
physical restraint
Under Section 15F (1), it is noted that an approved provider 
must not use a physical restraint unless:
a. An Approved Health Practitioner Who Has Day-To-Day 
Knowledge Of The Consumer Has:
(i) Assessed The Consumer As Posing A Risk Of Harm To 
The Consumer Or Any Other Person, And As Requiring 
The Restraint; And
(ii) Documented The Assessment, Unless The Use Of 
The Restraint Is Necessary In An Emergency; And
b. Alternatives To Restraint Have Been Used For The 
Consumer To The Extent Possible; And
c. The Alternatives To Restraint That Have Been Considered 
Or Used Have Been Documented, Unless The Use Of The 
Restraint Is Necessary In An Emergency.
Notably, in stark contrast, under Section 15G(1), a provider 
must not use chemical restraint unless:
a. A medical practitioner or nurse practitioner has assessed 
the consumer as requiring the restraint and has prescribed 
the medication the use of which is, or is involved in, 
the restraint; and
b. The practitioner's decision to use the restraint has been 
recorded in the care and services plan documented for 
the consumer in accordance with the Aged Care Quality 
Standards set out in Schedule 2.
Under 15G(2) b, having decided to use restraint (ie after using 
restraint) the provider must ensure that the care and services 
plan identifies:
(i) The Consumer's Behaviours That Are Relevant To 
The Need For The Restraint;
(ii) The Alternatives To Restraint That Have Been Used (If 
Any);
(iii) The Reasons The Restraint Is Necessary (If Known By 
The Approved Provider);
4 |   PEISAH Et Al.
(iv) The Information (If Any) Provided To The Practitioner 
That Informed The Decision To Prescribe The 
Medication.
Such requirements for chemical restraint suggest merely docu-
mentation of alternatives to restraints (“if any” have been used) 
after use.
3.3 | Consent requirements
Under Section 15F (e) with regard to physical restraint, the pro-
vider must have the informed consent of the consumer or their 
representative to the use of the restraint, with no such require-
ment mandated for chemical restraint under 15G, only “if it is 
practicable to do so” or “after the restraint starts to be used.” 
Obtaining consent after treatment is not consent. Moreover, 
the requirement to inform the “consumer's representative” is 
contrary to the law and best practice, which stipulates that an 
attempt should always be made to obtain consent from the per-
son themselves first, followed by a proxy decision-maker if 
necessary.3,14 The current requirement presumes that all peo-
ple requiring chemical restraint lack capacity to give consent, 
contrary to the presumption of capacity outlined above.
4 |  CONCLUSION
The Principles are a start in promoting best practice with re-
gard to restraints, particularly physical restraints, as are flow-
on initiatives such as the Self-assessment tool for recording 
consumers receiving psychotropic medications21 and our 
own work with WebsterCare.22 However, the less rigorous 
requirements for chemical restraint, with optional assess-
ment, and consent sometimes obtained, after restraint use, 
and from the person's “representative,” rather than the person 
themselves first followed by their proxy decision-maker, do 
not address the status quo of poor practice and may serve to 
codify it. Restraint is restraint, whether physical or chemical. 
To make one more permissible, or easier to obtain, endorses 
its use and sends a strong message that it is a preferable op-
tion for managing changed behaviours. The key message 
should not be which type of restraint is preferable, but rather 
to, as the legislation purports, minimise restraint.
“Quality of Care” with regard to the use of chemical 
restraint means restraint used as last resort with stringent 
safeguards such as mandatory consent and in least restric-
tive form (ie for chemical restraint, minimal dose, short du-
ration, avoiding polypharmacy), and monitoring for effect 
and harm.23 Clearly, other strategies for improving practice 
around chemical restraint and consent are required, beyond 
this legislation.
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